ArticleClinical ophthalmology (Auckland, N.Z.)2015
Prostaglandin-associated periorbitopathy in latanoprost users.
Article in Clinical ophthalmology (Auckland, N.Z.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Impact of prostaglandin-related antiglaucoma medication use on levator aponeurosis advancement outcomes.International ophthalmology · 2026Article
- Evaluation of Risk Factors for Unilateral Aponeurotic Ptosis Using the Fellow Eye as Control: A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation.Journal of clinical medicine · 2025Article
- Real-world large sample evaluation of drug-related blepharoptosis: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.Therapeutic advances in drug safety · 2025Article
- Evaluation of the Effect of Topical Prostaglandin Analog Treatment on Orbital Structures in Open-Angle Glaucoma with Computed Tomography.Journal of clinical medicine · 2024Article
- Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment.Turkish journal of ophthalmology · 2023Article
- Facial Fat Fitness: A New Paradigm to Understand Facial Aging and Aesthetics.Aesthetic plastic surgery · 2021Review
- Distribution ofOphthalmology and therapy · 2020Article
- Article
- Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists.Investigative ophthalmology & visual science · 2020Article
- Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2020Article
- Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4.BMJ open ophthalmology · 2020Article
- Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging.PloS one · 2019Observational
- The effect of air pulse-driven whole eye motion on the association between corneal hysteresis and glaucomatous visual field progression.Scientific reports · 2018Article
- Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Periorbital changes associated with prostaglandin analogs in Korean patients.BMC ophthalmology · 2017Article
- Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and TherapeuticsArticle
- The eyelash follicle features and anomalies: A review.Journal of optometryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe investigated the incidence of prostaglandin-associated periorbitopathy (PAP) in subjects with glaucoma treated with latanoprost ophthalmic solution. SUBJECTS AND
methodsOne eye and the forehead in 22 subjects were evaluated. All patients had used latanoprost for more than 1 year (range, 12 to 45 months; mean, 26.0 months) and were prostaglandin F2α analogue treatment-naïve. Digital photographs of the subjects obtained before latanoprost therapy and at the last examination were compared retrospectively. Four signs of PAP (deepening of the upper eyelid sulcus (DUES), upper eyelid ptosis, flattening of the lower eyelid bags, and inferior scleral show) and supplemental side effects around the eyelids (eyelash growth, poliosis, and eyelid pigmentation) were judged to be negative or positive by three independent observers. If the observers unanimously rated a sign as positive, the result was defined as positive.
resultsTwelve subjects (54.5%) had no apparent signs. Three subjects were judged to have DUES (13.6%), and two subjects each were judged to have flattening of the lower eyelid bags and eyelid pigmentation (9.0%). The other signs were judged as positive in only one subject each, respectively (4.5%). A univariate logistic regression analysis showed no significant associations between any of the signs and age, sex, or the duration of therapy.
conclusionLatanoprost induced DUES, upper eyelid ptosis, flattening of the lower eyelid bags, inferior scleral show, and supplemental side effects around the eyelids; however, the rates of such occurrence might be relatively low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.